Lineage Cell Therapeutics (LCTX) Net Margin (2010 - 2026)
Lineage Cell Therapeutics (LCTX) reported Net Margin of 278.96% for Q1 2026, up 12231.0% on a YoY basis from N/an in Q1 2025, and down 214.02% quarter-over-quarter from 244.66% in Q4 2025.
Lineage Cell Therapeutics (LCTX) Net Margin (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics has reported Net Margin for 17 years, with the latest figure at 278.96% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin rose 12231.0% year-over-year to 278.96%; the trailing twelve-month figure through Mar 2026 stood at 77.08% (up 11180.0% YoY), and the FY2025 full-year result was 435.33%, down 23971.0% from the prior year.
- Net Margin for Q1 2026 stood at 278.96%, down from 244.66% in the prior quarter.
- The five-year high for Net Margin was 244.66% in Q4 2025, with the low at 698.95% in Q2 2025.
- Historically, Net Margin has averaged 249.0% across 5 years, with a median of 185.96% in 2022.
- Annual changes were most pronounced in 2022 — Net Margin soared 82077 bps — and 2023, when it slumped 38852 bps.
- Lineage Cell Therapeutics' Net Margin stood at 332.22% in 2022, then soared by 32 bps to 225.77% in 2023, then surged by 50 bps to 113.32% in 2024, then soared by 316 bps to 244.66% in 2025, then slumped by 214 bps to 278.96% in 2026.
- The last three Net Margin figures came in at 278.96% (Q1 2026), 244.66% (Q4 2025), and 92.91% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn | -278.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -278.96% |
| Dec 31, 2025 | 244.66% |
| Sep 30, 2025 | -92.91% |
| Jun 30, 2025 | -698.95% |
| Mar 31, 2025 | -401.26% |
| Dec 31, 2024 | -113.32% |
| Sep 30, 2024 | -79.41% |
| Jun 30, 2024 | -410.01% |
| Mar 31, 2024 | -454.16% |
| Dec 31, 2023 | -225.77% |
| Sep 30, 2023 | -574.48% |
| Jun 30, 2023 | -161.33% |
| Mar 31, 2023 | -184.58% |
| Dec 31, 2022 | -332.22% |
| Sep 30, 2022 | -185.96% |
| Jun 30, 2022 | -148.96% |
| Mar 31, 2022 | -135.44% |
| Dec 31, 2021 | -56.02% |
| Sep 30, 2021 | -345.11% |
| Jun 30, 2021 | -969.73% |